Skip to main content
Premium Trial:

Request an Annual Quote

Edward Maggio, Andrew Parkinson, Sangeeta Bhatia, Douglas Hixson, John Quinn, and William Crowley Jr.


MultiCell has added four scientists to its scientific advisory board, the company said last week. The new board members are Edward Maggio, Andrew Parkinson, Sangeeta Bhatia, and Douglas Hixson.

Maggio was previously nominated to Multicell’s board of directors, but opted to join the scientific advisory board instead, the company said. He is the CEO and a founder of Cengent Therapeutics, and is the former president and CEO of ImmunoPharmaceutics. He has a PhD from the University of Michigan, and conducted post doctoral research at the University of California, San Francisco.

Parkinson is the founder, chairman, and CEO of XenoTech, which is Multicell’s exclusive marketing and distribution partner for two cell lines used in drug discovery, the company said. Parkinson has served as associate director of the Center for Environmental and Occupational Health and professor of pharmacology and toxicology at the University of Kansas Medical Center. He holds a PhD from the University of Guelph.

Bhatia has been an associate professor in the department of bioengineering and an associate adjunct professor in gastroenterology in the department of medicine at the University of California, San Diego, and is also a member of the UCSD Cancer Center, MultiCell said. She serves on a number of scientific advisory boards, on several National Institutes of Health and National Science Foundation panels, and on the Xenogenics board of directors. Bhatia earned her MD from Harvard Medical School, and holds a PhD from the Massachusetts Institute of Technology.

Hixson is the vice president and co-founder of Prothera Biologics, a professor of medicine and pathology at Brown University, and director of the COBRE Center for Cancer Research at Rhode Island Hospital. He holds a BS and MS from Purdue University, and a PhD from the University of Texas in Houston.

Bioveris announced on May 24 that it has named John Quinn and William Crowley Jr. to its board of directors.

Quinn is a senior operating executive with PolyOne, where he has been group vice president of the elastomers and performance additives business since 1998, Bioveris said. Prior to this, he was a general manager in the plastics business of General Electric.

Crowley is a CPA and independent business advisor to several companies, Bioveris said. In 2002, he retired from Arthur Andersen, with which he had a 32-year career, most recently as managing partner of that company’s Baltimore office.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.